RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jaydutt Vadgama to Antineoplastic Agents

This is a "connection" page, showing publications Jaydutt Vadgama has written about Antineoplastic Agents.
Connection Strength

1.480
  1. Wu Y, Sarkissyan M, Mcghee E, Lee S, Vadgama JV. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat. 2015 Jun; 151(3):529-39.
    View in: PubMed
    Score: 0.302
  2. Wang P, Phan T, Gordon D, Chung S, Henning SM, Vadgama JV. Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Mol Nutr Food Res. 2015 Feb; 59(2):250-61.
    View in: PubMed
    Score: 0.293
  3. Hao Q, Wu Y, Vadgama JV, Wang P. Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies. Biomolecules. 2022 09 16; 12(9).
    View in: PubMed
    Score: 0.126
  4. Hao Q, Wang P, Dutta P, Chung S, Li Q, Wang K, Li J, Cao W, Deng W, Geng Q, Schrode K, Shaheen M, Wu K, Zhu D, Chen QH, Chen G, Elshimali Y, Vadgama J, Wu Y. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052.
    View in: PubMed
    Score: 0.111
  5. Deng W, Li J, Dorrah K, Jimenez-Tapia D, Arriaga B, Hao Q, Cao W, Gao Z, Vadgama J, Wu Y. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 May; 125:109956.
    View in: PubMed
    Score: 0.105
  6. Cao W, Li J, Hao Q, Vadgama JV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 02 21; 21(1):29.
    View in: PubMed
    Score: 0.098
  7. Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, Hao Q, Kemp KT, Elshimali Y, Iyer R, Nguyen KT, Zheng S, Chen G, Chen QH, Wang G, Vadgama JV, Wu Y. Targeting of PP2Cd By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo. Antioxid Redox Signal. 2019 06 10; 30(17):1983-1998.
    View in: PubMed
    Score: 0.094
  8. Hamilton N, Austin D, M?rquez-Garb?n D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
    View in: PubMed
    Score: 0.090
  9. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-? and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90.
    View in: PubMed
    Score: 0.074
  10. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014 Feb; 44(2):403-11.
    View in: PubMed
    Score: 0.068
  11. Wang P, Vadgama JV, Said JW, Magyar CE, Doan N, Heber D, Henning SM. Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem. 2014 Jan; 25(1):73-80.
    View in: PubMed
    Score: 0.068
  12. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 01; 70(13):5475-85.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support